VYNE Therapeutics (VYNE) Raw Materials (2021)

VYNE Therapeutics (VYNE) posted Raw Materials of $3.3 million for Q4 2021.

VYNE Therapeutics (VYNE) Raw Materials (2021) Analysis & Trends

VYNE Therapeutics' Raw Materials history runs 1 years deep, the most recent figure standing at $3.3 million for Q4 2021.

  • Quarterly Raw Materials changed N/A year-over-year to $3.3 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $3.3 million (changed N/A YoY) and the FY2021 annual result came in at $3.3 million, changed N/A from the prior year.
  • Raw Materials was $3.3 million for Q4 2021 at VYNE Therapeutics.
  • Across five years, Raw Materials topped out at $3.3 million in Q4 2021 and bottomed at $3.3 million in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 VYNE Therapeutics 1.19 Bn 1.16 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2021 3.30 Mn